Literature DB >> 17675730

A modified two-step treatment for actinomycetoma.

M Ramam1, Radhakrishna Bhat, Taru Garg, Vinod K Sharma, R Ray, M K Singh, U Banerjee, C Rajendran.   

Abstract

BACKGROUND: Combination antibiotic regimens are effective in the treatment of actinomycetoma but many treatment schedules require supervised parenteral therapy for prolonged periods. We describe a schedule that includes parenteral medication in an initial, short phase followed by a longer phase of oral medication.
METHODS: Sixteen patients with clinically diagnosed mycetoma, who did not show any evidence of a fungal etiology, were treated presumptively for actinomycetoma. Evidence of actinomycotic infection was found on microscopy of granules / discharge and / or histopathological examination in eight (50%) patients. The treatment consisted of an intensive phase (Step 1) with gentamicin, 80 mg twice daily, intravenously and cotrimoxazole, 320/1600 mg twice daily orally for four weeks. This was followed by a maintenance phase with cotrimoxazole and doxycycline, 100 mg twice daily till all sinuses healed completely. The treatment was continued for 5-6 months.
RESULTS: Treatment response was assessed monthly. At the end of the intensive phase, there was a significant improvement in all 16 patients. Nine patients who continued the maintenance phase of the regimen had complete healing of sinuses with marked reductions in swelling and induration in 2.4 +/- 1.7 months. Maintenance treatment was continued for a mean of 9.1 +/- 4.3 months in these patients. Six patients have remained free of disease activity during a follow-up period of 11.1 +/- 4.2 months after treatment was stopped. Two patients developed leucopenia and thrombocytopenia necessitating withdrawal of cotrimoxazole.
CONCLUSION: This regimen was effective in treating actinomycetoma. The short duration of the phase requiring parenteral therapy makes it convenient to administer.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17675730     DOI: 10.4103/0378-6323.32888

Source DB:  PubMed          Journal:  Indian J Dermatol Venereol Leprol        ISSN: 0378-6323            Impact factor:   2.545


  5 in total

1.  Disseminated orbital actinomycetoma: a case report.

Authors:  Nita Umesh Shanbhag; Sumita Karandikar; Pooja Anil Deshmukkh
Journal:  Indian J Ophthalmol       Date:  2010 Jan-Feb       Impact factor: 1.848

2.  Molecular diagnosis of Actinomadura madurae infection by 16S rRNA deep sequencing.

Authors:  Stephen J Salipante; Dhruba J Sengupta; Daniel R Hoogestraat; Lisa A Cummings; Bronwyn H Bryant; Catherine Natividad; Stephanie Thielges; Peter W Monsaas; Mimosa Chau; Lindley A Barbee; Christopher Rosenthal; Brad T Cookson; Noah G Hoffman
Journal:  J Clin Microbiol       Date:  2013-10-09       Impact factor: 5.948

3.  Linezolid: A novel treatment option for the treatment of a non-responsive case of actinomycotic mycetoma.

Authors:  Suman Patra; Gridharan Senthilnathan; M Ramam; Sudheer Arava; Neetu Bhari
Journal:  Indian J Dermatol Venereol Leprol       Date:  2021 May-Jun       Impact factor: 2.545

Review 4.  Mycetoma: An Update.

Authors:  Vineet Relhan; Khushbu Mahajan; Pooja Agarwal; Vijay Kumar Garg
Journal:  Indian J Dermatol       Date:  2017 Jul-Aug       Impact factor: 1.494

5.  Madurella mycetomatis, the main causative agent of eumycetoma, is highly susceptible to olorofim.

Authors:  Wilson Lim; Kimberly Eadie; Mickey Konings; Bart Rijnders; Ahmed H Fahal; Jason D Oliver; Mike Birch; Annelies Verbon; Wendy van de Sande
Journal:  J Antimicrob Chemother       Date:  2020-04-01       Impact factor: 5.790

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.